Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

These results strongly support the favourable benefit-to-risk ratio of K-877 add-on therapy in combination with statin treatment.